PROGRAMME 2019

Download: Booklet – Programme and Faculty 2019

 

Thursday, January 31


 
DINNER BUFFET MEETING (registration required)
 
19:30–20:45    When should treatment be started at relapse and how to follow patients during remission and therapy?
Joan Bladé

 

Friday, February 1


 

GRAND CONFERENCE ROOM

08:15–08:20    Welcome
Heinz Ludwig and Jesús San-Miguel
 
08:20–08:45    From MGUS to multiple myeloma: Insights into the pathophysiology
Dirk Hose
 
08:45–09:10    The role of bone marrow stroma in multiple myeloma
Charlotte Pawlyn
 
09:10–09:35    NGS in MM, clinical relevance and prospects for the future
Leo Rasche
 
09:35–10:05    Expert discussion: Bringing the evolving wealth of information into clinical perspective
Moderator: Heinz Ludwig
Participants: Dirk Hose, Charlotte Pawlyn, Leo Rasche
  • What is different between transient MGUS and permanent MGUS?
  • Which genomic changes indicate progression to MM?
  • Are changes in BM environment during transformation from MGUS to MM the cause the consequence of transformation?
  • Will NGS improve selection of individualized therapy in MM?
  • Questions from audience
10:05–10:35    Coffee Break
 
10:35–11:00    NGF for immune profiling, MRD assessment and detection of circulating plasma cells
Bruno Paiva
 
11:00–11:25    Diagnostic workup in patients with paraproteinemia
Francesca Gay
 
11:25–12:15    Workshops
  • Renal disease in multiple myeloma: Pathophysiology and treatment Mark Cook
  • Pathophysiology and Management of myeloma bone disease Evangelos Terpos
  • How I treat extramedullary myeloma and plasma cell leukemia? Joan Blade
 
12:15–13:15    Lunch Buffet
 
13:15–13:40    Imaging in myeloma bone disease
Elena Zamagni
 
13:40–14:05    Risk stratification of smoldering myeloma and recommendations for management
María-Victoria Mateos
 
14:05–14:30    Optimizing induction and consolidation therapy in TE patients
Philippe Moreau
 
14:30–14:55    Strategies for optimizing maintenance treatment
Michele Cavo
 
14:55–15:25    Expert discussion: best approaches in early MM and TE patients
Moderator: Philippe Moreau
Participants: Michele Cavo, María-Victoria Mateos, Charlotte Pawlyn
  • What are the best markers for progression of SMM?
  • What is the optimal number of cycles for induction and consolidation?
  • Is there any sense in switching to another protocol if patient do not respond to the first line TX?
  • Who benefits from consolidation?
  • What is the optimal maintenance therapy for HR-disease?
15:25–15:55    Coffee Break
 
15:55–16:45    Workshops (programme repeated)
 
16:45–17:10    Treatment options for elderly fit patients
Mario Boccadoro
   
17:10–17:35    Management of elderly, unfit and frail patients
Alessandra Larocca
   
17:35–18:05    Expert discussion: Management of elderly patients
Moderator: Heinz Ludwig
Participants: Mario Boccadoro, Alessandra Larocca, Evangelos Terpos
  • How to improve induction therapy?
  • Optimal approach in high-risk patients?
  • Is maintenance therapy a valuable option for elderly patients?
  • Strategies for patients not responding to induction?
  • Questions from the audience

19:00               Delegate Dinner

 

Saturday, February 2


 

BREAKFAST MEETING (registration required)
 
07:45–08:15    Transplantation and cellular therapies in MM
Mohamad Mohty
 
 

GRAND CONFERENCE ROOM

08:30–09:00    Keynote lecture: The roadmap to cure patients with multiple myeloma?
Jesus San Miguel
   
09:00–09:25    Impact of monoclonal and bispecific antibodies in myeloma therapy today and tomorrow
Niels van de Donk
   
09:25–09:50    How I treat high risk disease
Pieter Sonneveld
   
09:50–10:20    Panel discussion: How to cure more patients with myeloma?
Moderators: Jesús San-Miguel
Participants: Pieter Sonneveld, Hermann Einsele, Niels van de Donk
  • Risk adapted therapy or ‚optimal‘ treatment for all?
  • Can we overcome the negative impact of HR disease with presently available approaches
  • Is there any guidance for stopping therapy in patients with prolonged MRDneg?
  • Should early treatment be recommended in case of change from MRDneg to MRDpos?
  • The best approach in HR disease
  • Questions from the audience
10:20–10:50    Coffee break
    
10:50–11:15    Sequencing in relapsed/refractory disease
Heinz Ludwig

11:15–11:35    Innovative drugs for myeloma therapy
Enrique Ocio
   
11:35–12:00    Strategies for optimizing CAR-T cell and other cellular therapies
Hermann Einsele
   
12:00–12:30    Panel discussion: How to optimize treatment of relapsed or refractory disease?
Moderator: Jesus San Miguel
Participants: Enrique Ocio, Hermann Einsele, Heinz Ludwig
  • Are there golden rules for relapse therapy?
  • Options after failure of anti-CD38 therapy
  • What are the prospects of new, still experimental drugs and strategies?
  • What to do if all new approved therapies fail?
  • Questions from the audience
12:30–12:55    New developments in amyloidosis
Giampaolo Merlini
   
12:55–13:00    Closure of the meeting
 
from 13:00      Lunch buffet
 
 
Programme and themes are subject to change!